Literature DB >> 25399644

The resistance tetrad: amino acid hotspots for kinome-wide exploitation of drug-resistant protein kinase alleles.

Fiona P Bailey1, Veselin I Andreev, Patrick A Eyers2.   

Abstract

Acquired resistance to targeted kinase inhibitors is a well-documented clinical problem that is potentially fatal for patients to whom a suitable back-up is not available. However, protein kinase alleles that promote resistance to inhibitors can be exploited experimentally as gold-standards for "on"- and "off"-target validation strategies and constitute a powerful resource for assessing the ability of new or combined therapies to override resistance. Clinical resistance to kinase inhibitors is an evident in all tyrosine kinase-driven malignancies, where high rates of mutation drive tumor evolution toward the insidious drug-resistant (DR) state through a variety of mechanisms. Unfortunately, this problem is likely to intensify in the future as the number of target kinases, approved inhibitors, and clinical indications increase. To empower the analysis of resistance in kinases, we have validated a bioinformatic, structural, and cellular workflow for designing and evaluating resistance at key mutational hotspots among kinome members. In this chapter, we discuss how mutation of amino acids in the gatekeeper and hinge-loop regions (collectively termed the "resistance tetrad") and the DFG motif represent an effective approach for generating panels of DR kinase alleles for chemical genetics and biological target validation.

Entities:  

Keywords:  ATP; Cancer; Drug; Gatekeeper; Hinge; Inhibitor; Kinase; Kinome; Ligand; Mutation; Polypharmacology; Resistance

Mesh:

Substances:

Year:  2014        PMID: 25399644     DOI: 10.1016/B978-0-12-397918-6.00005-7

Source DB:  PubMed          Journal:  Methods Enzymol        ISSN: 0076-6879            Impact factor:   1.600


  10 in total

1.  The Tribbles 2 (TRB2) pseudokinase binds to ATP and autophosphorylates in a metal-independent manner.

Authors:  Fiona P Bailey; Dominic P Byrne; Krishnadev Oruganty; Claire E Eyers; Christopher J Novotny; Kevan M Shokat; Natarajan Kannan; Patrick A Eyers
Journal:  Biochem J       Date:  2015-04-01       Impact factor: 3.857

2.  TNIK Is a Therapeutic Target in Lung Squamous Cell Carcinoma and Regulates FAK Activation through Merlin.

Authors:  Pedro Torres-Ayuso; Elvira An; Katherine M Nyswaner; Ryan C Bensen; Daniel A Ritt; Suzanne I Specht; Sudipto Das; Thorkell Andresson; Raul E Cachau; Roger J Liang; Amy L Ries; Christina M Robinson; Simone Difilippantonio; Brad Gouker; Laura Bassel; Baktiar O Karim; Chad J Miller; Benjamin E Turk; Deborah K Morrison; John Brognard
Journal:  Cancer Discov       Date:  2021-01-25       Impact factor: 38.272

3.  Constitutive Activity in an Ancestral Form of Abl Tyrosine Kinase.

Authors:  Saadat U Aleem; Barbara P Craddock; W Todd Miller
Journal:  PLoS One       Date:  2015-06-19       Impact factor: 3.240

4.  A Partial Response to Reintroduced Chemotherapy in a Resistant Small Cell Lung Cancer Patient After Priming with RRx-001.

Authors:  Bryan Oronsky; Scott Caroen; Karen Zeman; Mary Quinn; Christina Brzezniak; Jan Scicinski; Pedro Cabrales; Tony R Reid; Jane B Trepel; Nacer D Abrouk; Christopher Larson; Arnold Oronsky; Harry E Lybeck; Regina M Day; Corey A Carter
Journal:  Clin Med Insights Oncol       Date:  2016-11-06

5.  Use of the Polo-like kinase 4 (PLK4) inhibitor centrinone to investigate intracellular signalling networks using SILAC-based phosphoproteomics.

Authors:  Dominic P Byrne; Christopher J Clarke; Philip J Brownridge; Anton Kalyuzhnyy; Simon Perkins; Amy Campbell; David Mason; Andrew R Jones; Patrick A Eyers; Claire E Eyers
Journal:  Biochem J       Date:  2020-07-17       Impact factor: 3.857

Review 6.  Phosphoproteomics Meets Chemical Genetics: Approaches for Global Mapping and Deciphering the Phosphoproteome.

Authors:  Jan Jurcik; Barbara Sivakova; Ingrid Cipakova; Tomas Selicky; Erika Stupenova; Matus Jurcik; Michaela Osadska; Peter Barath; Lubos Cipak
Journal:  Int J Mol Sci       Date:  2020-10-15       Impact factor: 5.923

7.  Inhibition of KIT Tyrosine Kinase Activity: Two Decades After the First Approval.

Authors:  Lillian R Klug; Christopher L Corless; Michael C Heinrich
Journal:  J Clin Oncol       Date:  2021-04-02       Impact factor: 44.544

8.  'Up with the LRRK': a phosphorylated Rab10 assay for evaluation of LRRK2 activity and inhibitor engagement.

Authors:  Patrick A Eyers
Journal:  Biochem J       Date:  2016-09-15       Impact factor: 3.857

9.  New tools for carbohydrate sulfation analysis: heparan sulfate 2-O-sulfotransferase (HS2ST) is a target for small-molecule protein kinase inhibitors.

Authors:  Dominic P Byrne; Yong Li; Krithika Ramakrishnan; Igor L Barsukov; Edwin A Yates; Claire E Eyers; Dulcé Papy-Garcia; Sandrine Chantepie; Vijayakanth Pagadala; Jian Liu; Carrow Wells; David H Drewry; William J Zuercher; Neil G Berry; David G Fernig; Patrick A Eyers
Journal:  Biochem J       Date:  2018-08-14       Impact factor: 3.857

10.  New tools for evaluating protein tyrosine sulfation: tyrosylprotein sulfotransferases (TPSTs) are novel targets for RAF protein kinase inhibitors.

Authors:  Dominic P Byrne; Yong Li; Pawin Ngamlert; Krithika Ramakrishnan; Claire E Eyers; Carrow Wells; David H Drewry; William J Zuercher; Neil G Berry; David G Fernig; Patrick A Eyers
Journal:  Biochem J       Date:  2018-08-14       Impact factor: 3.857

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.